A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

• Published in: Diabetes therapy Vol. 9; no. 4; pp. 1511 - 1532
• Main Authors: Pereira, Maria J., Lundkvist, Per, Kamble, Prasad G., Lau, Joey, Martins, Julian G., Sjöström, C. David, Schnecke, Volker, Walentinsson, Anna, Johnsson, Eva, Eriksson, Jan W.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-08-2018; Springer; Springer Nature B.V
• Subjects: Analysis; Antidiabetics; Biological markers; Body mass index; Cardiology; Care and treatment; Clinical trials; Comorbidity; Complications and side effects; Dapagliflozin; Diabetes; Diagnosis; Endocrinology; Evidence-based medicine; Exenatide; Glucagon; Glucose; Glucose tolerance tests; Glycerol; Insulin; Internal Medicine; Lipid metabolism; Medicine; Medicine & Public Health; Metabolism; Obesity; Original Research; Single nucleotide polymorphisms; Single-nucleotide polymorphism; Weight control; Weight loss; Sweden; Obesity; Single-nucleotide polymorphism; Lipid metabolism; Dapagliflozin; Exenatide; Weight loss
• ISSN: 1869-6953; 1869-6961; 1869-6961
• DOI: 10.1007/s13300-018-0449-6

Introduction
The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly (QW) among adults with obesity and without diabetes.
Methods
In the primary trial, adults with obesity and without diabetes [
n
= 50; 18–70 years; body mass index (BMI) 30–45 kg/m
2
] were randomized to double-blind oral dapagliflozin 10 mg (DAPA) once daily plus subcutaneous long-acting exenatide 2 mg QW (ExQW) or placebo over 24 weeks, followed by an open-label extension from 24–52 weeks during which all participants received active treatment. Primary results have been published previously. This analysis evaluated: (1) the effects of DAPA + ExQW on changes in substrates [free fatty acids (FFAs), glycerol, beta-OH-butyrate, and glucose], hormones (glucagon and insulin), and insulin secretion [insulinogenic index (IGI)] via an oral glucose tolerance test (OGTT) and (2) associations between bodyweight loss and baseline characteristics (e.g., BMI), single-nucleotide polymorphisms (SNPs) associated with the GLP-1 pathway, and markers of glucose regulation.
Results
Compared with placebo at 24 weeks, 2-h FFAs post-OGTT increased (mean difference, +20.4 μmol/l;
P
< 0.05), and fasting glucose, 2-h glucose post-OGTT, and glucose area under the concentration-time curve (AUC) decreased with DAPA + ExQW [mean differences, −0.68 mmol/l [
P
< 0.001], −2.20 mmol/l (
P
< 0.01), and −306 mmol/l min (
P
< 0.001), respectively]. Glucagon, glycerol, beta-OH-butyrate, and IGI did not differ by treatment group at 24 weeks. Over 52 weeks, DAPA + ExQW decreased fasting insulin, 2-h post-OGTT insulin, and insulin AUC. Among DAPA + ExQW-treated participants, for each copy of the SNP variant rs10010131 A allele (gene
WFS1
), bodyweight decreased by 2.4 kg (
P
< 0.05). Lower BMI and a lower IGI were also associated with greater bodyweight loss with DAPA + ExQW.
Conclusions
Metabolic effects with DAPA + ExQW included less FFA suppression versus placebo during the OGTT, suggesting compensatory lipid mobilization for energy production when glucose availability was reduced because of glucosuria. The expected increase in glucagon with DAPA did not occur with DAPA + ExQW coadministration. Bodyweight loss with DAPA + ExQW was associated with the SNP variant rs10010131 A allele, lower baseline adiposity (BMI), and lower baseline insulin secretion (IGI). These findings require further validation.
Funding
AstraZeneca